Medicine
Sotyktu 6 mg tablet
Sotyktu 6 mg tablet is a prescription medicine containing Deucravacitinib for oral use, marketed by ER Squibb & Sons, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store SOTYKTU tablets at 20°C to 25°C (68°F to 77°F), excursions permitted…
Key facts
- Active ingredient (INN)
- Deucravacitinib
- Brand
- Sotyktu
- Strength
- 6 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets
- Marketing authorisation holder
- ER Squibb & Sons
- Manufacturer
- ER Squibb & Sons
- Origin register
- US FDA, United States
- Storage
- Store SOTYKTU tablets at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AF07 Deucravacitinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 September 2022
- Identifiers
- RxCUI 2612092, 2612098DailyMed set ID ff4d7258-5068-4cdf-9692-8cae04c3198eNDC 0003-0895Application NDA214958
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle, plastic | 0003-0895-11 | ER Squibb & Sons | 9 September 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Deucravacitinib is a tyrosine kinase 2 inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Deucravacitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DeucravacitinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SOTYKTU prescribing information (ER Squibb & Sons) · U.S. National Library of Medicine, DailyMed
- Sotyktu: European public assessment report (EPAR) · European Medicines Agency
Need Sotyktu 6 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.